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An important key to clinical management of prostate cancer patients is to determine
early those who will benefit from primary treatment and are not good candidates for
active surveillance (AS). We describe a 67-year-old gentleman with a long history of sta-
ble prostate-specific antigen (PSA) levels and a negative biopsy. After slight PSA rise and
low volume Gleason score 6 biopsy, the patient was considered for primary treatment or
AS. A multiparametric (MP)-MRI exam revealed a suspicious lesion in the anterior apex of
the prostate. Biopsies were carried out on a 3D-ultrasound prostate biopsy system with
MRI-fusion. The location of the target area was challenging and could have been missed
using standard 12-core biopsy template. The pathology determined Gleason 3+4 disease
in 30% of the core from this region. Consequently, the patient underwent radiotherapy
(RT). MP-MRI was also used to follow the changes from pre- to post-RT.
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INTRODUCTION
Prostate cancer is multifocal and heterogeneous, with foci of dif-
ferent Gleason scores (GS) commonly present. The treatment
decision-making process among active surveillance (AS), radio-
therapy (RT), and surgery can be a difficult one and is primarily
based on clinical–pathological data such as prostate-specific anti-
gen (PSA), digital rectal exam (DRE), and prostate biopsy infor-
mation, the latter of which is compromised by such heterogeneity.
The clinically accepted method for the diagnosis of prostate cancer
is transrectal ultrasound (TRUS)-guided biopsies following a 12-
core template. TRUS does not reliably visualize cancer foci, with up
to 30% of tumors being isoechoic (1) and a roughly 50:50 chance
of documenting cancer in hypoechoic lesions. Utilizing multi-core
template is still relatively a tumor-undirected approach and has
the potential to miss high grade and/or anterior lesions that may
dictate outcome.
BACKGROUND
We describe a 67-year-old gentleman who presented for eval-
uation of recently diagnosed cT1N0M0 prostate cancer. After
many stable PSAs in the low 4 ng/ml range over 6 years, PSA
rose slightly to 4.7 ng/ml a year ago. TRUS biopsy at this time
was negative for malignancy, but showed a focus of high grade
prostatic intraepithelial neoplasia in the left lateral base. Seven
months later, the PSA rose to 6.2 ng/ml and a repeat biopsy was
performed, which showed Gleason 3+ 3= 6 prostatic adenocar-
cinoma involving two cores with <10% involvement from the
left lateral base and left apex. TRUS-estimated prostate volume
was 65 cc with a PSA density 0.095 ng/ml. Review of systems was
positive for mild daytime urinary frequency and nocturia one to
two times per night. DRE revealed a large, smooth prostate with no
discrete abnormality. At this time, he was a candidate for either AS
or primary treatment. Three months later (PSA= 7.2 ng/ml), the
patient underwent multiparametric (MP)-MRI exam. MP-MRI,
consisting of T2-weighted, T1 dynamic contrast-enhanced MRI
(DCE-MRI), and diffusion-weighted MRI (DWI) with derived
apparent diffusion coefficient (ADC) revealed a suspicious lesion
in the anterior apex of the prostate. MP-MRI was acquired on a GE
Discovery MR750/3 T using standard clinical protocols. Figure 1A
shows an area of nodular hypointensity on the axial T2-weighted
image marked with an arrow. The same area is associated with
low ADC values (mean± SD: 842± 67µm2/s) relative to the sur-
rounding peripheral zone tissue (mean± SD: 1858± 168µm2/s;
p-value< 0.001, Student’s t -test). DCE-MRI was analyzed with
in-house developed software (2) and the area indicated in the
heat map in Figure 1 was associated with fast contrast uptake
and gradual washout. The gadolinium contrast pharmacokinetic
parameters for this area: K trans [volume transfer constant between
plasma and extravascular space (EES)] and kep (rate constant
between EES and plasma) are 0.351 and 0.705 min−1, respec-
tively (3). In contrast, the same constants for the surrounding
peripheral zone tissue were markedly lower: K trans= 0.175 min−1
and kep= 0.292 min−1. Based on these findings, in addition to a
PSA of 7.2 ng/ml, the patient underwent MRI-ultrasound-directed
prostate biopsies.
We used a commercially available 3D-ultrasound (US) prostate
biopsy system that allows for MRI-fusion at the time of the
procedure (Artemis system, Eigen, Sun Valley, CA, USA). This is
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FIGURE 1 | Multiparametric-MRI findings and directed prostate biopsy
of the index lesion. (A) T2-weighted MRI and ADC map, with arrows
indicating tumor area; (B) DCE-MRI intensity map with the lightest (yellow)
part representing the areas of rapid contrast wash-in and gradual washout;
and (C) tumor (yellow) and prostate (brown) contours. Both volumes were
transferred to Artemis™ for fusion to the real-time ultrasound prior to
prostate biopsy; 3D representation of the tumor with biopsy needle path
shown.
accomplished by (i) utilizing software to contour the prostate and
biopsy target(s) (Figure 1B, “Target”); (ii) loading outlined MRI
volumes into the system for fusion; (iii) using a TRUS end-fire
probe to generate a 3D prostate image by rotating the probe cra-
dle; and (iv) registration of the triangulated gland surfaces from
both modalities using an adaptive-focus deformable model (4).
The system tracking computes the needle trajectory, its core posi-
tion, and its depth (Figure 1C). After biopsy acquisition, the tip
of the biopsy is marked with ink for accurate localization of the
tissue sample.
The biopsies were taken from a suspicious region not seen on
TRUS but identified by MP-MRI in the apex. It should be noted
that obtaining biopsies of this area is sometimes challenging and
may not be sampled using a typical 12-core template.
DISCUSSION
The pathology review determined GS 3+ 4 in 30% of the core
from the suspicious region (Figure 2). Thus, the patient was not
FIGURE 2 | H&E stain of MP-MRI-ultrasound-directed prostate biopsy.
The ink stain indicates that the tumor is located on the tip of the biopsy. The
region in the red box is at 20× magnification and shows Gleason
score=3+4.
considered as a candidate for AS and he underwent RT. The patient
was enrolled in an institutional investigator-initiated RT trial in
which higher doses of radiation are delivered to the MP-MRI
identified dominant lesion in half of the patients. He was ran-
domized to the standard arm and the entire prostate and proximal
seminal vesicles received 80 Gy in 40 fractions. Repeat MP-MRIs
were performed 3 months post-RT. In Figure 3, the T2-weighted
MRI, ADC map, and contrast-versus-time curves are shown pre-
(A) and 3 months post-treatment (B) in two prostate regions. The
comparison illustrates the disappearance of the lesion on the post-
treatment T2 and ADC images. Post-treatment ADC values for the
lesion (blue) were 1576± 80µm2/s and for normal prostate (red)
were 1467± 146µm2/s. While quite distinct pre-treatment, the
contrast-versus-time curves post-RT were similar with a temporal
pattern characteristic for normal prostate.
CONCLUDING REMARKS
Even with 12-core template grid-like sampling of the prostate,
TRUS-guided biopsies have been reported to miss 30% of can-
cers at the time of first biopsy (5), and studies have shown limited
accuracy in tumor localization when correlated with pathologic
specimens (6).
T2-weighted MRI provides an excellent depiction of prostate
anatomy with regions of healthy peripheral zone prostate tis-
sue demonstrating higher signal intensity than prostate cancer.
DWI is an imaging technique, which is sensitive to diffusion of
water molecules and provides details about tissue architecture.
The derived ADC values are significantly lower in tumor than in
normal prostate. The lower the ADC value, the greater the chance
of diagnosing GS≥7 disease (7). DCE-MRI has also demonstrated
that greater and earlier enhancement is seen in tumor versus nor-
mal tissue. DCE-MRI is a measure of tissue vascularity and hence
angiogenesis. MP-MRI has been shown to improve the sensitivity
and specificity of tumor localization (8). Combining these meth-
ods, results in better correlation with pathologic findings, with
accuracy of up to 85% (9).
Death due to prostate cancer occurs late, but is significantly
greater in men observed versus those treated primarily. An impor-
tant key to clinical management is to determine early those who are
not good candidates for AS. Recent reports show a 25–35% rate of
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FIGURE 3 | Comparison of MP-MRI exam before and after radiotherapy. T2-weighted MRI, ADC map, and contrast-versus-time curves pre- (A) and
3 months post-RT (B) of two prostate regions are shown: malignant lesion pre-treatment (blue) and healthy appearing PZ (red).
upgrade in prostatectomy specimens in patients considered can-
didates for AS (10). The reported rates of conversion depend on
the length of follow-up. For instance, these rates range from 20 to
33% in a review of several AS clinical trials, with median follow-up
time from 1.3 to 3.5 years (11). In a single institution study with the
longest available follow-up,Klotz et al. reported rates of conversion
of 24.3, 36.5, and 45% at 5, 10, and 15 years follow-up, respectively
(12). Patient anxiety and quality-of-life considerations may lead to
conversion to treatment in the absence of biological progression
(13). Klotz et al. reported that 6% of patients discontinued AS
due to personal preference rather than clinical progression (12).
Therefore, in men undergoing AS, we estimate a 20–30% rate of
conversion to treatment by 3 years, suggesting that men in whom
early conversion to treatment is recommended are probably those
who have been undergraded and/or understaged by conventional
assessments. Identifying early, those patients who will benefit from
primary treatment and are not good candidates for AS, is of para-
mount importance. MRI/US-fused biopsy offers a more accurate
way to target determinant lesions that might have been missed.
With the trend toward more conservative management of prostate
cancer, it is crucial to be able to identify such lesions early, to
develop strategies that require fewer biopsies at each session, and
to apply imaging techniques to better follow determinant lesions
for progression and biopsy.
The advantages over standard ultrasound-guided biopsies are
not only illustrated in the case presented but have been suggested
by other studies. In a meta-analysis of 16 studies, Schoots et al.
found that MRI-guided biopsy had a 20% better rate of detecting
significant prostate cancer as compared to TRUS-guided biopsy
(14). Moreover, MRI-guided biopsy was almost twice as likely
to avoid detecting insignificant prostate cancer as compared to
TRUS-guided biopsy. Thus, MRI guided biopsy is a promising
procedure for avoiding the oversampling and overtreatment of
insignificant disease. One can envision a lower frequency of biop-
sies and fewer directed biopsies. MP-MRI is becoming widely
accepted and used in the selection and management of patients
for AS. Given the emergence of technology that allows for fusion
between MP-MRI and real-time ultrasound, clinicians can now
direct biopsies toward regions most suspicious for harboring sig-
nificant cancer based on MP-MRI. This opens the door for a
paradigm shift in how patients are selected and managed for AS.
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